GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death

Figures & data

Figure 1. A flow chart of this study. EC: endometrial cancer; GLP1R: glucagon-like peptide 1 receptor; RT-qPCR: quantitative reverse transcription PCR. RL95-2, HEC-1A, KLE, Ishikawa and AN3CA are human EC cell lines.

Figure 2. Up-regulation of GLP1R in EC tissue specimens. (A) RT-qPCR for GLP1R mRNA expression between tumour and normal samples. (B,C) Western blotting for GLP1R protein between tumour and normal samples. (D) Immunohistochemistry of GLP1R protein in tumour and normal samples. Positive cells are stained by DAB and appear as brown, and cell nucleus is stained by haematoxylin as blue. *p < 0.05 and ****p < 0.0001.

Figure 3. GLP1R protects EC cells from ferroptosis. (A,B) Intracellular ROS level ofAN3CA cells treated with siGLP1R or GLP-1 agonist. (C–F) Expression of SLC7A11, FTH1 and GPX4 in AN3CA cells treated with siGLP1R or GLP-1 agonist. ****p < 0.001.

Figure 4. Suppression of GLP1R attenuates the inhibitory effects of ferrostatin-1 on ferroptosis of EC cells. (A,B) Intracellular ROS level of AN3CA cells treated with ferrostatin-1 and/or siGLP1R. (C–F) Expression of SLC7A11, FTH1 and GPX4 in AN3CA cells treated with ferrostatin-1 and/or siGLP1R. ****p < 0.001.

Data availability statement

The datasets analysed during the current study are available from the corresponding author on reasonable request.